Actually, nemolizumab, a humanized monoclonal antibody against IL-31Rα which blocks signaling from IL-31, provides improvement of pruritis in patients with AD in a 16-week, double-blind, phase 3 trial (58). The gene discussed is IL31RA; the disease is Alzheimer disease.